Y-mAbs Shifts Focus To Approved Drug, Pipeline After Omburtamab CRL

 
• By Alaric DeArment
  
Y-mAbs got a complete response letter for 131I-omburtamab in metastasis from neuroblastoma • Source: Shutterstock

More from New Products

More from Scrip